Cyclooxygenase-2 expression in proliferative Ki-67-positive breast cancers is associated with poor outcomes
- 165 Downloads
In order to investigate the implications of cyclooxygenase-2 (COX-2) expression in combination with Ki-67 on breast cancer outcomes, the COX-2 and Ki-67 expression levels and other clinicopathologic parameters were investigated in 861 breast cancers. Clinicopathological parameters and survival were investigated in association with the expression levels of both COX-2 and Ki-67 using univariate and multivariate analyses. COX-2 expression was positive in 493 (57.3%) of invasive tumors. COX-2 was associated with favorable markers, but was not related to survival outcome by itself. However, COX-2 in proliferative tumors [COX-2(+)/Ki-67(+)] were significantly associated with unfavorable factors and the worst survival, but COX-2 in non-proliferative tumors [COX-2(+)/Ki-67(−)] showed significantly favorable parameters and better outcomes. COX-2(−)/Ki-67(any) showed intermediate prognosis. The statistical significance was maintained in stage-matched and multivariate analyses. The results of present study suggest that COX-2 expression is a common event in breast cancers and may play in a different ways by the proliferation status of the tumor cells. Further studies should be carried out to verify the role of COX-2 by proliferative conditions of breast tumor cells.
KeywordsBreast neoplasms Cyclooxygenase-2 Proliferation Ki-67 Prognosis Progression
A major part of this study was presented at the 34th Annual San Antonio Breast Cancer Symposium, Poster session, December 6-10, 2011, in San Antonio, TX, USA. This work was supported by the Brain Korea 21 Project for Medical Science, Yonsei University, and in part by a grant-in-aid from Sanofi-Aventis Pharmaceutical Co. and Dong-A Pharmaceutical Co.
Conflicts of interest
The authors have declared no potential conflicts of interest.
- 19.Jalava P, Kuopio T, Juntti-Patinen L et al (2006) Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 48:674–682. doi: 10.1111/j.1365-2559.2006.02402.x PubMedCrossRefGoogle Scholar
- 22.Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. Springer, New YorkGoogle Scholar
- 24.Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795. doi: 10.1200/JCO.2009.25.6529 PubMedCrossRefGoogle Scholar
- 28.Glover JA, Hughes CM, Cantwell MM et al (2011) A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancer. Br J Cancer 105:13–17. doi: 10.1038/bjc.2011.204 PubMedCrossRefGoogle Scholar
- 33.Food and Drug Administration (FDA) (2010) FDA begins process to remove breast cancer indication from Avastin label. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm237172.htm. Accessed 16 Dec 2010